Correction: Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) (Genetics in Medicine, (2018), 20, 9, (899-909), 10.1038/s41436-018-0039-z)

on behalf of the ACMG Professional Practice and Guidelines Committee

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

In the original version of this Article, the Statement on Conflict of Interest originally submitted by the authors was not published and should have read: Disclosure: R.E.H. has served as a consultant for Array Biopharma. C.Y.H. has served as a consultant and has received research support from MyoKardia. D.P.J. has served as a consultant for Array Biopharma, Eidos Therapeutics, Glaxo Smith Kline, Invitae, MyoKardia, and Pfizer. M.R.G.T. has served as a consultant for Array Biopharma, Guidepoint Global, and Wellpoint, Inc., and has served as a speaker for GeneDx. M.V. is employed by Invitae Corporation. The other authors declare no conflicts of interest. Furthermore, in the Acknowledgements section we neglected to state that: This article is an abbreviated version of “Genetic Evaluation of Cardiomyopathy—a Heart Failure Society of America Practice Guideline,” published in Journal of Cardiac Failure, and on which the American College of Medical Genetics and Genomics and the Heart Failure Society of America collaborated. The PDF and HTML versions of the Article have now been corrected with the above.

Original languageEnglish (US)
JournalGenetics in Medicine
DOIs
StatePublished - Jan 1 2019

    Fingerprint

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this